Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMT in Chronic Heart Failure
NCT07490054Phase 1Recruiting
- Start
- Oct 2025
- Primary completion
- Sep 2027
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MTP-101 in chronic heart failure (CHF). Primary endpoints: Number of Adverse Events at 180 days and Study Drug Adherence at 14 days. Started Oct 2025; status: recruiting.
02
Drugs
MTP-101
03
Conditions
chronic heart failure (CHF)
Beyond the preview
Go deeper on NCT07490054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07490054.